Skip to content

AnaptysBio, Inc. ANAB Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Eli Lilly logo
Eli LillyLLY
1.4%+0.9pp
Pfizer logo
PfizerPFE
7.8%+4.6pp
Amgen logo
AmgenAMGN
4.5%-2.0pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5%+0.6pp
Biogen logo
BiogenBIIB
9%-3.2pp

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.7B+180%

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

Based on trailing twelve months.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s free cash flow yield?
AnaptysBio, Inc. (ANAB) reported free cash flow yield of 0.3% in Q1 2026.
How has AnaptysBio, Inc.'s free cash flow yield changed year-over-year?
AnaptysBio, Inc.'s free cash flow yield increased by 101.4% year-over-year, from -19.1% to 0.3%.
What is the long-term trend for AnaptysBio, Inc.'s free cash flow yield?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s free cash flow yield has grown at a -44.2% compound annual growth rate (CAGR), from -8.4% to 1.5%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.